These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 17390370)

  • 21. New silyl ether reagents for the absolute stereochemical determination of secondary alcohols.
    Williamson RT; Barrios Sosa AC; Mitra A; Seaton PJ; Weibel DB; Schroeder FC; Meinwald J; Koehn FE
    Org Lett; 2003 May; 5(10):1745-8. PubMed ID: 12735767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of experimental strategies for the development of chiral chromatographic methods based on diastereomer formation.
    Srinivas NR
    Biomed Chromatogr; 2004 May; 18(4):207-33. PubMed ID: 15162384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Separation of naproxen enantiomers by supercritical/subcritical fluid chromatography.
    Yang Y; Su B; Yan Q; Ren Q
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):815-8. PubMed ID: 15951148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chirality and its implications in transdermal drug development.
    Reddy IK; Kommuru TR; Zaghloul AA; Khan MA
    Crit Rev Ther Drug Carrier Syst; 2000; 17(4):285-325. PubMed ID: 10958245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Albendazole sulfoxide enantiomers: preparative chiral separation and absolute stereochemistry.
    Lourenço TC; Batista JM; Furlan M; He Y; Nafie LA; Santana CC; Cass QB
    J Chromatogr A; 2012 Mar; 1230():61-5. PubMed ID: 22341660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of the absolute configuration of a chiral oxadiazol-3-one calcium channel blocker, resolved using chiral chromatography, via concerted density functional theory calculations of its vibrational circular dichroism, electronic circular dichroism, and optical rotation.
    Stephens PJ; Devlin FJ; Gasparrini F; Ciogli A; Spinelli D; Cosimelli B
    J Org Chem; 2007 Jun; 72(13):4707-15. PubMed ID: 17516678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chiral ionic liquids: synthesis, properties, and enantiomeric recognition.
    Yu S; Lindeman S; Tran CD
    J Org Chem; 2008 Apr; 73(7):2576-91. PubMed ID: 18311997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of recent advances in mass spectrometric methods for gas-phase chiral analysis of pharmaceutical and biological compounds.
    Wu L; Vogt FG
    J Pharm Biomed Anal; 2012 Oct; 69():133-47. PubMed ID: 22579598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of absolute configurations by X-ray crystallography and 1H NMR anisotropy.
    Harada N
    Chirality; 2008 May; 20(5):691-723. PubMed ID: 17935143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential properties of enantiomers of commercially available racemates.
    Gulati V
    J Indian Med Assoc; 2007 Apr; 105(4):173-4, 176. PubMed ID: 17822184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Looking forward in pharmaceutical process chemistry.
    Davies IW; Welch CJ
    Science; 2009 Aug; 325(5941):701-4. PubMed ID: 19661417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug discovery beyond the 'rule-of-five'.
    Zhang MQ; Wilkinson B
    Curr Opin Biotechnol; 2007 Dec; 18(6):478-88. PubMed ID: 18035532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First total synthesis of antitumor natural product (+)- and (-)-pericosine A: determination of absolute stereo structure.
    Usami Y; Takaoka I; Ichikawa H; Horibe Y; Tomiyama S; Ohtsuka M; Imanishi Y; Arimoto M
    J Org Chem; 2007 Aug; 72(16):6127-34. PubMed ID: 17628106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biocatalysis for pharmaceutical intermediates: the future is now.
    Pollard DJ; Woodley JM
    Trends Biotechnol; 2007 Feb; 25(2):66-73. PubMed ID: 17184862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of racemisation of the enantiomers of glitazone drug compounds at different pH using chiral HPLC and chiral CE.
    Jamali B; Bjørnsdottir I; Nordfang O; Hansen SH
    J Pharm Biomed Anal; 2008 Jan; 46(1):82-7. PubMed ID: 17942259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ligand-based approach to in silico pharmacology: nuclear receptor profiling.
    Mestres J; Martín-Couce L; Gregori-Puigjané E; Cases M; Boyer S
    J Chem Inf Model; 2006; 46(6):2725-36. PubMed ID: 17125212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simulated moving bed chromatography for the separation of enantiomers.
    Rajendran A; Paredes G; Mazzotti M
    J Chromatogr A; 2009 Jan; 1216(4):709-38. PubMed ID: 19004446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The determination of the absolute configurations of chiral molecules using vibrational circular dichroism (VCD) spectroscopy.
    Stephens PJ; Devlin FJ; Pan JJ
    Chirality; 2008 May; 20(5):643-63. PubMed ID: 17955495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Timely synthetic support for medicinal chemists.
    Potoski J
    Drug Discov Today; 2005 Jan; 10(2):115-20. PubMed ID: 15718160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.